Toshiba introduces exclusive and FDA-cleared CT Myocardial Perfusion on its Aquilion ONE and Aquilion ONE ViSION Edition CT systems.
To improve cardiac diagnoses with simplified dose reduction technology, Toshiba announces the FDA clearance of its industry-exclusive CT Myocardial Perfusion capability. Available on Toshiba’s Aquilion ONE and Aquilion ONE ViSION Edition CT systems, Myocardial Perfusion allows clinicians to visualise myocardial ischemia with CT, providing a clinical and operational solution to make work flow.
The Myocardial Perfusion on Toshiba’s 320-detector-row CTs shows blood flow and anatomy within the coronary arteries to help determine the viability of the heart muscle. This enables clinicians to make faster and more accurate decisions on whether to undergo revascularisation of coronary blockages. Toshiba’s CT Myocardial Perfusion puts patient experience first with shorter exam times and significantly lower radiation exposure, when compared with traditional coronary artery disease (CAD) evaluation methods.
“Heart disease has remained the number one cause of death in the United States, according to the Centers for Disease Control and Prevention, and new CT technology is helping diagnose cardiac disease sooner,” said Satrajit Misra, senior director, CT Business Unit, Toshiba. “The Aquilion ONE’s ability to capture the entire heart in a single rotation and its Myocardial Perfusion capability allow clinicians to make better decisions on treatment. Additionally, Toshiba’s simplified dose reduction technology, AIDR 3D, ensures that CT dose and safety is not a choice hospitals or patients should have to make.”
Toshiba will showcase its Myocardial Perfusion technology at this year’s American College of Cardiology (ACC) annual meeting in Washington, D.C., March 29–April 2, 2014 (Booth #2323).
13 March 2014